Monday, October 3, 2022


Biotechnology News Magazine

Epiphany Technology Acquisition Corp. Announces Appointment of Officers and Directors

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Epiphany Technology Acquisition Corp. (the “Company”) announced today that the company’s Board of Directors (the “Board”) has approved an increase in the size of the Board from seven (7) directors to eleven (11) directors and elected Ross HaghighatStephen SherwinRonald Eastman and Louis Lange as members of the Board.

In addition, the Board appointed Mr. Ross Haghighat as Co-Chief Executive Officer of the Company. The Board determined that each of Messrs. Stephen SherwinRonald Eastman and Louis Lange is an “independent director” as defined in the Nasdaq listing standards and applicable rules of the Securities and Exchange Commission.

While the Company may pursue an initial business combination with a partner company in any business or industry, it initially focused on technology businesses. The public markets in general, as well as the SPAC market in particular, remain challenged, making it difficult for us to partner with a high-quality technology company at an attractive valuation. We decided to expand our focus to include the biotechnology industry, where we believe the market backdrop remains more favorable. To this end, we have augmented our management team and board with highly qualified individuals with significant experience building, operating and investing in biotechnology companies.

The Company is blank check company organized for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine